Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04624906
Title Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia (BRAWM)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sunnybrook Health Sciences Centre
Indications

Waldenstroem's macroglobulinemia

Therapies

Acalabrutinib + Bendamustine + Rituximab

Age Groups: senior | adult
Covered Countries CAN


No variant requirements are available.